Anivance AI is reshaping preclinical research with a fully integrated, animal-free platform aligned with the U.S. FDA’s 2025 roadmap for New Approach Methodologies (NAMs).
We accelerate safer, faster drug development by combining organ-on-chip technology, high-throughput phenotypic profiling, and predictive AI.
Our platform delivers insights across cancer, lung diseases, rare conditions, and advanced drug delivery — replacing animal models with human-relevant, scalable systems.
We’ve built validated models for the lung, liver, heart, kidney, and tumors, partnering with 50+ physicians and 6 clinical institutions worldwide.
Backed by Taiwan’s largest tech firms, Anivance holds 25 patents and was nominated for the LUSH Prize in Science.
We pioneer a “No Animals, No Delays, Just Human Data” vision.
Company Details
- Employees
- 12
- Founded
- -
- Address
- Rm. 6, 2f., No. 150, Sec. 2, Shengyi Rd., Zhubei City, Hsinchu County 302058, Taiwan., 新竹市,300,taiwan, Province Of China
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.anivance.io/
- Keywords
- Clinical Trials Solutions Provider.
- HQ
- 新竹市
Anivance Ai Questions
Anivance Ai's website is https://www.anivance.io/
Anivance Ai's LinkedIn profile is https://tw.linkedin.com/company/anivanceai
Anivance Ai has
12 employees.
View email and phone details for 12
employees at Anivance Ai.
Anivance Ai's industry is
Biotechnology Research
Anivance Ai's top competitors are
Acrocyte Therapeutics,
醫華生技股份有限公司cytoaurora,
北京大橡科技有限公司,
Aiii.ai類神經網路股份有限公司,
Tsmc,
Emulate, Inc.,
Mimetas,
Microdoctor Biomedical 微一生醫,
Wesley Ai Inc.,
Darwin Precisions 達運精密.
Anivance Ai's categories are Biotechnology Research
Anivance Ai's founding year is 2024
